[Breast cancer: a dynamic approach of cellular immunity and immunostimulation with an immunoadjuvant: P40 fraction. (author's transl)].
The study of the immune status of breast cancer patients with delayed hypersensitivity skin tests reveals a clear immune deficiency in comparison with a reference patients group. This immunstatus was significantly improved by an immunstimulation with the P40 fraction. The responsive capacity to an immunstimulation appears independant of the lymphnodes involvment, whereas, on the contrary, the initial degree of immune deficiency appears connected. The P40 fraction has an immunstimulant effect comparable with the BCG and has not occasioned any local or general undesirable reaction.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D003352:Corynebacterium; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D008408:Mastectomy; D008875:Middle Aged; D012882:Skin Tests
D000276:Adjuvants, Immunologic
Cancer du sein opérable. Appréciation dynamique de l'immunité cellulaire et de l'immuno-stimulation par l'adjuvant P40.